Found: 33
Select item for more details and to access through your institution.
Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications.
- Published in:
- American Journal of Hematology, 2019, v. 94, p. S28, doi. 10.1002/ajh.25428
- By:
- Publication type:
- Article
Progressive multifocal leukoencephalopathy in multiple myeloma.
- Published in:
- European Journal of Haematology, 2023, v. 110, n. 3, p. 322, doi. 10.1111/ejh.13909
- By:
- Publication type:
- Article
Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma.
- Published in:
- Oncology & Therapy, 2023, v. 11, n. 2, p. 263, doi. 10.1007/s40487-023-00228-5
- By:
- Publication type:
- Article
Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
- Published in:
- Frontiers in Immunology, 2018, p. N.PAG, doi. 10.3389/fimmu.2018.02551
- By:
- Publication type:
- Article
Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 6, p. 350, doi. 10.1016/j.clml.2024.03.005
- By:
- Publication type:
- Article
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 12, p. 882, doi. 10.1016/j.clml.2023.08.012
- By:
- Publication type:
- Article
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.
- Published in:
- 2023
- By:
- Publication type:
- journal article
Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 Deletion Treated With Eculizumab.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 11, p. e845, doi. 10.1016/j.clml.2021.06.019
- By:
- Publication type:
- Article
MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S422, doi. 10.1016/S2152-2650(21)01946-7
- By:
- Publication type:
- Article
Poster: MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S249, doi. 10.1016/S2152-2650(21)01569-X
- By:
- Publication type:
- Article
Oral Abstract: MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S202, doi. 10.1016/S2152-2650(21)01275-1
- By:
- Publication type:
- Article
Elotuzumab Promotes Self-Engagement of Signaling Lymphocytic Activation Molecule Family Member 7 (SLAMF7) Between Natural Killer (NK) and Multiple Myeloma (MM) Cells to Enhance Cytotoxicity.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S253, doi. 10.1016/j.clml.2018.07.156
- By:
- Publication type:
- Article
Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 2, p. 1, doi. 10.1038/s41408-022-00629-1
- By:
- Publication type:
- Article
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 10, p. 1, doi. 10.1038/s41408-020-00369-0
- By:
- Publication type:
- Article
Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone ± thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
- Published in:
- British Journal of Haematology, 2007, v. 139, n. 2, p. 224, doi. 10.1111/j.1365-2141.2007.06783.x
- By:
- Publication type:
- Article
Multiple airway plasmacytomas: A rare cause of proximal airway obstruction requiring tumor debulking.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Combination immune therapies to enhance anti-tumor responses by NK cells.
- Published in:
- Frontiers in Immunology, 2013, v. 4, p. 1, doi. 10.3389/fimmu.2013.00481
- By:
- Publication type:
- Article
Enhanced Responses to Tumor Immunization Following Total Body Irradiation Are Time-Dependent.
- Published in:
- PLoS ONE, 2013, v. 8, n. 12, p. 1, doi. 10.1371/journal.pone.0082496
- By:
- Publication type:
- Article
Detection of Intra-Tumor Self Antigen Recognition during Melanoma Tumor Progression in Mice Using Advanced Multimode Confocal/Two Photon Microscope.
- Published in:
- PLoS ONE, 2011, v. 6, n. 6, p. 1, doi. 10.1371/journal.pone.0021214
- By:
- Publication type:
- Article
Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation.
- Published in:
- PLoS ONE, 2010, v. 5, n. 5, p. 1, doi. 10.1371/journal.pone.0010436
- By:
- Publication type:
- Article
Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 23, p. 3746, doi. 10.1002/cncr.34987
- By:
- Publication type:
- Article
Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 22, p. 4198, doi. 10.1002/cncr.33809
- By:
- Publication type:
- Article
B‐cell maturation antigen chimeric antigen receptor T‐cell re‐expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor‐based combination therapy.
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 4, p. 851, doi. 10.1111/bjh.17397
- By:
- Publication type:
- Article
Dynamic holographic telecommunications components based on spatial light modulation with pixelated χ<sup>(2)</sup> polymers in a Fabry-Pérot cavity.
- Published in:
- Optical Engineering, 2000, v. 39, n. 3, p. 633, doi. 10.1117/1.602408
- By:
- Publication type:
- Article
A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.
- Published in:
- 2019
- By:
- Publication type:
- journal article
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Optimization of a self antigen for presentation of multiple epitopes in cancer immunity.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma.
- Published in:
- Cancers, 2021, v. 13, n. 2, p. 226, doi. 10.3390/cancers13020226
- By:
- Publication type:
- Article
CAR T-Cell Therapy Against B-Cell Maturation Antigen in Multiple Myeloma.
- Published in:
- Clinical Advances in Hematology & Oncology, 2018, v. 16, n. 12, p. 804
- By:
- Publication type:
- Article
Paraproteinemic neuropathies.
- Published in:
- Muscle & Nerve, 2024, v. 70, n. 2, p. 173, doi. 10.1002/mus.28164
- By:
- Publication type:
- Article
Systemic and Mucosal Immunity Is Elicited after Both Intramuscular and Intravaginal Delivery of Human Immunodeficiency Virus Type 1 DNA Plasmid Vaccines to Pregnant Chimpanzees.
- Published in:
- Journal of Infectious Diseases, 1999, v. 180, n. 4, p. 1351, doi. 10.1086/314978
- By:
- Publication type:
- Article